Scisparc advances the acquisition process of a leading vehicle importer company in israel with the provision of a bridge loan of $1.4 million

Tel aviv, israel, jan. 19, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it entered, as lender, into a bridge loan agreement (the "agreement) with a leading vehicle importer company in israel, as borrower (the "target company"), pursuant to which the target company received a bridge loan (the “bridge loan”) in the amount of $1.4 million, further to the previously-announced non-binding letter of intent (the “loi”) for the company to acquire the target company (the “acquisition”).
SPRC Ratings Summary
SPRC Quant Ranking